This past week of November, Ovohorse & Ovoclone have been awarded the ‘European Awards in Medicine 2024’ in the category of ‘Genetics’, thanks to the technological advances, innovations, and the research work carried out by the Ovohorse laboratory team on animal cloning and cell line preservation.
‘The European Awards’ brings together professionals and experts in the field of medicine from across Europe with the aim of promoting knowledge, quality, and research. This event took place in Budapest, at Gundel Palace, the most famous restaurant in Hungary.
Ovohorse & Ovoclone, companies belonging to the OVO Group, have a team of more than 150 professionals, including embryologists, doctors, veterinarians, and researchers. The team’s expertise in assisted reproduction techniques, genetics, and cryopreservation, together with their high success rates and the quality certifications that endorse their facilities, has made them one of the leading groups in reproductive medicine and cell cryopreservation.
The commitment to the application of science and the development of advanced methods has made Ovohorse & Ovoclone the first laboratory for cloning and cell line preservation in Spain. These techniques not only allow the cryopreservation of samples in the genetic bank for future conservation and use, but also make it possible to clone a genetically healthy animal identical to one that already exists.
Cloning covers several species, such as dogs, cats, horses, and camels. Ultimately, it preserves the genetic legacy of those that have played an important role, whether in breeding, competitions, or everyday life. One of the purposes of Ovohorse & Ovoclone is to go further with their technology and help preserve the genetic heritage of species, thus preventing the loss of their biological diversity and contributing to environmental sustainability and global biodiversity.
The latest innovation introduced by Ovohorse & Ovoclone is an international application for the auction of embryos and equine clones of high genetic quality, which will allow users to place bids from anywhere in the world.
This major project of the OVO Group is led by Enrique Criado Scholz, embryologist, laboratory director and CEO of the OVO Group, who brings with him extensive experience and a distinguished career in the field of reproductive medicine. Enrique was responsible for receiving the ‘The European Awards 2024’. This and the rest of the group’s international recognitions reflect the quality and endorse the work carried out in a constantly evolving field.